OTREXUP PFS

Peak

methotrexate

NDASUBCUTANEOUSSOLUTION
Approved
Oct 2013
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20

Mechanism of Action

Folic Acid Metabolism Inhibitors

Pharmacologic Class:

Folate Analog Metabolic Inhibitor

Clinical Trials (5)

NCT06590090Phase 2Not Yet Recruiting

Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment

Started Jul 2026
108 enrolled
Rheumatoid Arthritis
NCT07446400Phase 1Not Yet Recruiting

A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together

Started Mar 2026
48 enrolled
Healthy Volunteers
NCT07388498Phase 3Recruiting

A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled Gout

Started Feb 2026
270 enrolled
Uncontrolled Gout
NCT06895473Phase 2Recruiting

Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome

Started Jun 2025
26 enrolled
Hematopoietic and Lymphatic System Neoplasm
NCT06615050Phase 3Recruiting

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

Started Apr 2025
572 enrolled
Graft-versus-host Disease (GVHD)

Loss of Exclusivity

LOE Date
May 27, 2031
63 months away
Patent Expiry
May 27, 2031

Patent Records (5)

Patent #ExpiryTypeUse Code
8562564
Jan 24, 2026Expired
Product
9629959
Jan 24, 2026Expired
Product
11446441
Jan 24, 2026Expired
Product
9533102
Jan 24, 2026Expired
Product
8021335
Oct 4, 2026
Product